Back to Faculty
Faculty

Kevin Soares

2026 Sessions

Yes

Explore postoperative treatment strategies following liver resection, comparing the role of adjuvant hepatic arterial infusion (HAI) therapy with systemic adjuvant chemotherapy. Faculty will examine available evidence on recurrence risk reduction, survival outcomes, and toxicity profiles associated with each approach. The discussion will address practical considerations influencing treatment choice and provide new insight into whether adjuvant HAI offers added benefit over standard systemic chemotherapy.

Adjuvant HAI therapy has a meaningful role following liver resection compared with adjuvant systemic chemotherapy alone. Faculty will review clinical evidence demonstrating improved hepatic disease control and survival outcomes with HAI in selected patients, guiding learners through scenarios in which adjuvant HAI may optimize outcomes.

Debate Speaker

Saturday, September 26 1:30–1:50 PM
Gastrointestinal Cancers
Faculty

Kevin Soares

General Session

Is There a Role for Adjuvant HAI Following Liver Resection vs Adjuvant Chemotherapy?: Yes vs No

Explore postoperative treatment strategies following liver resection, comparing the role of adjuvant hepatic arterial infusion (HAI) therapy with systemic adjuvant chemotherapy...

  • Moderator
    • Cathy Eng, MD, FACP, FASCO
    • Yelena Janjigian, MD
  • Presenter
    • Sepideh Gholami, MD, MAS, FSSO, FACS
    • Kevin Soares
Gastrointestinal Cancers

Yes

Explore postoperative treatment strategies following liver resection, comparing the role of adjuvant hepatic arterial infusion (HAI) therapy with systemic adjuvant chemotherapy. Faculty will examine available evidence on recurrence risk reduction, survival outcomes, and toxicity profiles associated with each approach. The discussion will address practical considerations influencing treatment choice and provide new insight into whether adjuvant HAI offers added benefit over standard systemic chemotherapy.

Adjuvant HAI therapy has a meaningful role following liver resection compared with adjuvant systemic chemotherapy alone. Faculty will review clinical evidence demonstrating improved hepatic disease control and survival outcomes with HAI in selected patients, guiding learners through scenarios in which adjuvant HAI may optimize outcomes.

Debate Speaker

Saturday, September 26 1:30–1:50 PM
Gastrointestinal Cancers
Faculty

Kevin Soares

No

Explore postoperative treatment strategies following liver resection, comparing the role of adjuvant hepatic arterial infusion (HAI) therapy with systemic adjuvant chemotherapy. Faculty will examine available evidence on recurrence risk reduction, survival outcomes, and toxicity profiles associated with each approach. The discussion will address practical considerations influencing treatment choice and provide new insight into whether adjuvant HAI offers added benefit over standard systemic chemotherapy.

Faculty will review limitations of the available evidence for adjuvant HAI therapy after liver resection, including lack of randomized data, toxicity concerns, and challenges related to access and expertise. This discussion will address whether modern systemic therapies can provide comparable benefit without the added complexity of HAI.

Debate Speaker

Saturday, September 26 1:50–2:10 PM
Gastrointestinal Cancers
Faculty

Sepideh Gholami

MD, MAS, FSSO, FACS
Associate Professor of Surgical Oncology
Northwell Health Cancer Center

Dr. Sepideh Gholami is an Associate Professor of Surgery at Northwell Health. She is the Director of the Hepatic Artery Infusion Pump Program, and Director for Translational Research in Surgical Oncology with a joint appointment at Coldspring Harbor Laboratory. She is a surgeon-scientist focusing on the role of the tumor microenvironment in hepatobiliary malignancies. She obtained her degree from Stanford University and completed two fellowships at MSKCC specializing in Complex General Surgical Oncology, and Hepatobiliary Surgery.

Dr. Gholami is a national thought leader in the management of hepatobiliary malignancies with a vested interest in clinical trials. She serves as the co-Chair of the Colon subcommittee for SWOG and a member of the NCI Colon Cancer Task Force. Dr. Gholami has numerous peer-reviewed publications and has been the recipient of several research grants and prestigious awards including the Society of Surgical Oncology, Association of Academic Surgeons, and SWOG’s Young Investigator Award.
Back to top